Printer Friendly

CORTECH AMPLIFIES ITS 1992 FINANCIAL RELEASE

 DENVER, March 11 /PRNewswire/ -- In response to the requests for additional information on Cortech Inc.'s (NASDAQ: CRTQ) revenues stemming from the company's financial press release of March 10, the company announced that revenues increased from $2.0 million in 1991 to $5.2 million in 1992. This increase was attributable to the creation in 1992 of a research funding corporation, CP-0127 Development Corporation (CDC).
 Expenses increased from $6.0 million in 1991 to $9.5 million in 1992 primarily as a result of the company's expanding research and development activities and its growing infrastructure.
 These results will be presented in more detail in Cortech's year-end financial statements, which will be released at the end of March.
 Cortech's lead compound, a bradykinin antagonist called Bradycor, was successfully taken through Phase I safety studies in 1992. Although Phase II trials for sepsis with Bradycor have begun, no assurance can be given that the company's therapeutic approaches will lead to successful product launches and product revenues.
 Cortech is a Denver-based biopharmaceutical company focused on the design and development of two novel classes of drugs, bradykinin antagonists and neutrophil elastase inhibitors, to treat a broad range of inflammatory disorders. In addition, Cortech is developing a proprietary potential treatment for allergies and autoimmune diseases. Cortech common stock is listed as CRTQ on NASDAQ.
 -0- 3/11/93
 /CONTACT: David K. Crossen or Joseph L. Turner of Cortech, 303-650-1200/
 (CRTQ)


CO: Cortech Inc. ST: Colorado IN: MTC SU:

BB -- DV001 -- 4982 03/11/93 09:03 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 11, 1993
Words:252
Previous Article:NEWCOR, INC. ANNUAL MEETING OF SHAREHOLDERS HELD
Next Article:KAHLER CORPORATION TO REPURCHASE SHARES
Topics:


Related Articles
CORTECH ANNOUNCES INITIAL PUBLIC OFFERING
CORTECH CONVERSION RIGHTS EXPIRE
/C O R R E C T I O N -- CORTECH/
CORTECH FILLS SENIOR POSITIONS
CORTECH ANNOUNCES 1992 FINANCIAL RESULTS
CORTECH AMENDS IND TO INITIATE A PHASE II BRADYCOR TRIAL IN HEAD TRAUMA
CORTECH RELEASES FIRST QUARTER RESULTS
TO BUSINESS EDITO
CORTECH RELEASES THIRD QUARTER RESULTS
Cortech Announces Second Quarter and Six-Month Financial Results And New Board Member

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters